Carlos Romero-Gómez, Pablo López-Quirantes, José Antonio Reyes-Bueno and Ricardo Gómez-Huelgas. Patient with Systemic Lupus Erythematosus who Presented with Area Postrema Syndrome after COVID-19 Vaccination.
. 2022; 10(3):72-76. doi: 10.12691/AJMCR-10-3-8
postrema area syndrome, neuromyelitis optica, systemic lupus erythematosus, covid-19 vaccination
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6(9): 805-815. |
|
[2] | Patterson SL, Goglin SE. Neuromyelitis Optica. Rheum Dis Clin North Am. 2017; 43(4): 579-591. |
|
[3] | Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177-189. |
|
[4] | Camara-Lemarroy CR, Burton JM. Area postrema syndrome: A short history of a pearl in demyelinating diseases. Mult Scler. 2019; 25(3): 325-329. |
|
[5] | Flanagan EP. Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases. Contin (Minneap Minn). 2019; 25(3): 815-844. |
|
[6] | Chan KH, Lee CY. Treatment of neuromyelitis optica spectrum disorders. Int J Mol Sci. 2021; 22(16): 1-27. |
|
[7] | Kumar N, Graven K, Joseph NI, et al. Case Report: Postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review of Postvaccination Demyelination. Int J MS Care. 2020; 22(2): 85-90. |
|
[8] | Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19(3): 141-154. |
|
[9] | Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand. 2022; 145(1): 5-9. |
|
[10] | Khayat-Khoei M, Bhattacharyya S, Katz J, et al. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol. 2021; (0123456789). |
|
[11] | Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014; 13(3): 215-224. |
|
[12] | Badrawi N, Kumar N, Albastaki U. Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings. Radiol case reports. 2021; 16(12): 3864-3867. |
|
[13] | Chen S, Fan XR, He S, Zhang JW, Li SJ. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol Sci. 2021; 42(9): 3537-3539. |
|
[14] | Fujikawa P, Shah FA, Braford M, Patel K, Madey J. Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine. Cureus. 2021; 13(9):e17961. |
|
[15] | Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol. 2021; 358(January): 577606. |
|
[16] | Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020; 38: 101506. |
|
[17] | Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet (London, England). 2019; 394 (10206): 1352-1363. |
|
[18] | Araki M. Efficacy of the anti – IL-6 receptor antibody tocilizumab in neuromyelitis optica. Neurology. 2014; 82(15): 1302-1306. |
|
[19] | Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(22): 2114-2124. |
|
[20] | Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(7): 614-625. |
|